MARKET

SCYX

SCYX

Scynexis
NASDAQ
0.7608
-0.0192
-2.46%
After Hours: 0.7608 0 0.00% 16:04 05/13 EDT
OPEN
0.7600
PREV CLOSE
0.7800
HIGH
0.7745
LOW
0.7300
VOLUME
378.78K
TURNOVER
--
52 WEEK HIGH
1.310
52 WEEK LOW
0.5650
MARKET CAP
60.44M
P/E (TTM)
-4.4130
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target
TipRanks · 12h ago
Scynexis reports Q1 EPS (42c), consensus (12c)
TipRanks · 2d ago
SCYNEXIS GAAP EPS of -$0.42 misses by $0.30
Seeking Alpha · 2d ago
SCYNEXIS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 2d ago
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
Barchart · 2d ago
Weekly Report: what happened at SCYX last week (0504-0508)?
Weekly Report · 2d ago
SCYNEXIS grants new VP stock options for 125,000 shares at $0.93, plus 20,000 RSUs
PUBT · 05/07 01:15
SCYNEXIS ANNOUNCES INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/07 01:15
More
About SCYX
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).

Webull offers SCYNEXIS Inc stock information, including NASDAQ: SCYX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCYX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCYX stock methods without spending real money on the virtual paper trading platform.